Literature DB >> 23736534

Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders.

Raffaele Marfella1, Clara Di Filippo, Nicoletta Potenza, Celestino Sardu, Maria Rosaria Rizzo, Mario Siniscalchi, Emilio Musacchio, Michelangela Barbieri, Ciro Mauro, Nicola Mosca, Francesco Solimene, Maria Teresa Mottola, Aniello Russo, Francesco Rossi, Giuseppe Paolisso, Michele D'Amico.   

Abstract

AIMS: MicroRNAs (miRNAs) play an important role in the pathogenesis of structural alterations of the failing heart through their ability to regulate negatively the expression levels of genes that govern the process of adaptive and maladaptive cardiac remodelling. We studied whether LV reverse remodelling after CRT was associated with changes of circulating miRNAs in patients with heart failure (HF) and dyssynchrony. METHODS AND
RESULTS: A prospective, non-randomized self-control trial was performed in 81 patients with HF eligible for CRT. At baseline, to select the HF miRNA profile, we evaluated the expression of 84 miRNAs (implicated in the pathogenesis of structural alterations of the failing heart) in three groups of patients: healthy subjects (healthy group, n = 15); patients with HF (HF group, n = 81); and patients without HF matched for age, sex, and concomitant disease with HF patients (control group, n = 60). At 12 months, the selected miRNA profile was evaluated in plasma from responder (n = 55) and non-responder HF patients (n = 26) to CRT. In the test cohort, the HF patients were characterized by lower expression of 48 miRNAs (all P < 0.04) as compared with healthy subjects. In the validation cohort, the HF patients were characterized by lower expression of 24 miRNAs (all P < 0.03) as compared with control patients. At 12 months, 55 patients (68%) were considered responders and 26 non-responders to CRT (32%). Responders showed an increase in expression of 19 miRNAs (all P < 0.03) compared with baseline expression, whereas in the non-responders we observed an increase of six miRNAs (all P < 0.05) compared with baseline expression. At follow-up, miRNAs were differentially expressed between responders and non-responders. The responders were characterized by higher expression of five miRNAs (miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p; P < 0.01 for all) as compared with non-responders.
CONCLUSIONS: In responders, reverse remodelling is associated with favourable changes in miRNAs that regulate cardiac fibrosis, apoptosis, and hypertrophy.

Entities:  

Keywords:  Cardiac resynchronization therapy; Heart failure; MicroRNAs

Mesh:

Substances:

Year:  2013        PMID: 23736534     DOI: 10.1093/eurjhf/hft088

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  61 in total

Review 1.  Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction.

Authors:  Christian Schulte; Dirk Westermann; Stefan Blankenberg; Tanja Zeller
Journal:  World J Cardiol       Date:  2015-12-26

2.  Novel insights into a reputably irreversible process: combined mRNA and miRNA profiling of tissue from vesicourethral anastomotic stenosis after radical prostatectomy.

Authors:  T S Worst; K Daskalova; A Steidler; K Berner-Leischner; R Röth; B Niesler; C-A Weis; M C Kriegmair; P Erben; D Pfalzgraf
Journal:  World J Urol       Date:  2017-06-20       Impact factor: 4.226

Review 3.  Circulating microRNAs in cardiovascular diseases: from biomarkers to therapeutic targets.

Authors:  Feng Wang; Chen Chen; Daowen Wang
Journal:  Front Med       Date:  2014-12-01       Impact factor: 4.592

4.  Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach.

Authors:  Chiara Bianca Maria Platania; Rosa Maisto; Maria Consiglia Trotta; Michele D'Amico; Settimio Rossi; Carlo Gesualdo; Giovanbattista D'Amico; Cornel Balta; Hildegard Herman; Anca Hermenean; Franca Ferraraccio; Iacopo Panarese; Filippo Drago; Claudio Bucolo
Journal:  Br J Pharmacol       Date:  2019-05-09       Impact factor: 8.739

5.  Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people.

Authors:  Celestino Sardu; Raffaele Marfella; Gaetano Santulli
Journal:  J Cardiovasc Transl Res       Date:  2014-02-06       Impact factor: 4.132

6.  MicroRNAs Associated With Reverse Left Ventricular Remodeling in Humans Identify Pathways of Heart Failure Progression.

Authors:  Ravi Shah; Olivia Ziegler; Ashish Yeri; Xiaojun Liu; Venkatesh Murthy; Dustin Rabideau; Chun Yang Xiao; Kristina Hanspers; Arianna Belcher; Michael Tackett; Anthony Rosenzweig; Alexander R Pico; James L Januzzi; Saumya Das
Journal:  Circ Heart Fail       Date:  2018-02       Impact factor: 8.790

7.  Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial.

Authors:  Francis G Spinale; Timothy E Meyer; Craig M Stolen; Jennifer E Van Eyk; Michael R Gold; Suneet Mittal; Stacia M DeSantis; Nicholas Wold; John F Beshai; Kenneth M Stein; Kenneth A Ellenbogen
Journal:  Heart Rhythm       Date:  2018-11-24       Impact factor: 6.343

8.  Response to Letter Regarding Article, "Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study".

Authors:  Yonathan F Melman; Ravi Shah; Kirsty Danielson; Junjie Xiao; Bridget Simonson; Andreas Barth; Khalid Chakir; Gregory D Lewis; Zachary Lavender; Quynh A Truong; Andre Kleber; Ranendra Das; Anthony Rosenzweig; Yaoyu Wang; David Kass; Jagmeet P Singh; Saumya Das
Journal:  Circulation       Date:  2016-02-09       Impact factor: 29.690

Review 9.  Cellular and Molecular Aspects of Dyssynchrony and Resynchronization.

Authors:  Jonathan A Kirk; David A Kass
Journal:  Card Electrophysiol Clin       Date:  2015-12

Review 10.  Noncoding RNAs and myocardial fibrosis.

Authors:  Thomas Thum
Journal:  Nat Rev Cardiol       Date:  2014-09-09       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.